» Articles » PMID: 31493541

Functional Status As Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) has been increasingly offered to older adults with hematologic malignancies. However, optimal methods to determine fitness for alloHCT have yet to be defined. We evaluated the ability of a comprehensive geriatric assessment (CGA) to predict post-alloHCT outcomes in a single-center prospective cohort study of patients age 50 years and older. Outcomes included overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM). A total of 148 patients were included, with a median age of 62 years (range, 50 to 76 years). In multivariate regression analysis, several CGA measures of functional status were predictive of post-alloHCT outcomes, after adjusting for traditional prognostic factors. Any deficit in instrumental activities of daily living (IADL) was associated with inferior OS (hazard ratio [HR], 1.81, 95% confidence interval [CI], 1.07 to 3.08; P = .03) and PFS (HR, 1.85; 95% CI, 1.15 to 2.99; P = .01). A Medical Outcomes Study Physical Health scale (MOS-PH) score <85 was associated with inferior OS (HR, 1.96; 95% CI, 1.13 to 3.40; P = .02), PFS (HR, 1.75; 95% CI, 1.07 to 2.88; P = .03), and increased NRM (subdistribution HR, 2.57; 95% CI, 1.12 to 5.92; P = .03). MOS-PH score was also associated with the number of non-hematologic grade ≥3 adverse events within the first 100 days after alloHCT (rate ratio, 1.61; 95% CI, 1.04 to 2.49; P = .03). These findings support previous work suggesting that IADL is an important prognostic tool prior to alloHCT. MOS-PH is newly identified as an additional metric to identify older patients at higher risk of poor post-alloHCT outcomes, including toxicity and NRM.

Citing Articles

Health professionals' perceptions of prehabilitation before haematopoietic cell transplantation to optimise candidacy in older adults.

Guinan E, Heuston C, Sheill G, Chonghaile M, Orfali N Support Care Cancer. 2024; 32(7):465.

PMID: 38926198 PMC: 11208210. DOI: 10.1007/s00520-024-08659-0.


Recipient clonal hematopoiesis in allogeneic bone marrow transplantation for lymphoid malignancies.

Imus P, Pasca S, Tsai H, Aljawai Y, Cooke K, Walston J Blood Adv. 2024; 8(14):3849-3858.

PMID: 38640196 PMC: 11369632. DOI: 10.1182/bloodadvances.2023011761.


Transplantation and Cellular Therapy for Older Adults-The MSK Approach.

Lin R, Dahi P, Korc-Grodzicki B, Shahrokni A, Jakubowski A, Giralt S Curr Hematol Malig Rep. 2024; 19(2):82-91.

PMID: 38332462 PMC: 11126330. DOI: 10.1007/s11899-024-00725-y.


Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.

Sanchez Suarez M, Roldan A, Alarcon-Payer C, Rodriguez-Gil M, Poquet-Jornet J, Puerta Puerta J Pharmaceutics. 2024; 16(1).

PMID: 38258066 PMC: 10818903. DOI: 10.3390/pharmaceutics16010055.


Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.

Sung A, Koll T, Gier S, Racioppi A, White G, Lew M Transplant Cell Ther. 2024; 30(4):415.e1-415.e16.

PMID: 38242440 PMC: 11009062. DOI: 10.1016/j.jtct.2024.01.062.


References
1.
Loprinzi C, Laurie J, Wieand H, Krook J, Novotny P, Kugler J . Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol. 1994; 12(3):601-7. DOI: 10.1200/JCO.1994.12.3.601. View

2.
Deschler B, Ihorst G, Schnitzler S, Bertz H, Finke J . Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation: a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 2018; 53(5):565-575. DOI: 10.1038/s41409-017-0021-4. View

3.
Podsiadlo D, Richardson S . The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991; 39(2):142-8. DOI: 10.1111/j.1532-5415.1991.tb01616.x. View

4.
Heidenreich S, Ziagkos D, de Wreede L, van Biezen A, Finke J, Platzbecker U . Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biol Blood Marrow Transplant. 2016; 23(1):44-52. DOI: 10.1016/j.bbmt.2016.09.027. View

5.
Kelly M, Dunstan F, Lloyd K, Fone D . Evaluating cutpoints for the MHI-5 and MCS using the GHQ-12: a comparison of five different methods. BMC Psychiatry. 2008; 8:10. PMC: 2265280. DOI: 10.1186/1471-244X-8-10. View